Variability of the in vivo metabolism of clozapine

Clinical Neuropharmacology

Volumn 31, Issue 6, 2008, Pages 347-352

  Raedler, Thomas J ^a,b,c   Hinkelmann, Kim ^a   Wiedemann, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF CALGARY   (Canada)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

Clozapine; N desmethylclozapine; NDMC; Plasma level; Psychopharmacology; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORCLOZAPINE; DRUG DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; BIOAVAILABILITY; BLOOD; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 59849100133     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31815cba61     Document Type: Article

References (30)

1. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
2. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New Engl J Med 1997;337:809-815.
3. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715-723.
4. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610.
5. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry 2003;60:82-91.
6. Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 2004; 177:07-216.
7. Davies MA, Compton-Toth BA, Hufeisen SJ, et al. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions. Psychopharmacology (Berl) 2005;178: 451-460.
8. Palego L, Biondi L, Giannaccini G, et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:473-480.
9. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 2000; 148:83-89.
10. Fabrazzo M, La Pia S, Monteleone P, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology 2002; 27:1050-1055.
11. Guitton C, Abbar M, Kinowski JM, et al. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1998;18:470-476.
12. Diaz FJ, de Leon J, Josiassen RC, et al. Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr Res 2005;72: 131-135.
13. Kurz M, Hummer M, Kemmler G, et al. Long-term pharmacokinetics of clozapine. Br J Psychiatry 1998;173:341-344.
14. Carillo JA, Herraiz AG, Ramos SI, et al. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 1998;18:311-316.
15. Fang J, Coutts RT, McKenna KF, et al. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol 1998;358: 592-599.
16. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997;44:439-446.
17. Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001;41:823-832.
18. Ozdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol 2001;21:398-407.
19. Heiser P, Schüler-Springorum M, Schulte E, et al. Pharmacokinetics of clozapine and its metabolites in hippocampal HT22 cells. Eur J Pharmacol 2003; 476:167-172.
20. Doude van Troostwijk LJ, Koopmans RP, Vermeulen HD, et al. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. Eur J Pharm Sci 2003;20: 451-457.
21. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353: 1209-1223.
22. Perry PJ, Bever KA, Arndt S, et al. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998;44:733-738.
23. Seppälä NH, Leinonen EV, Lehtonen ML, et al. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 1999;85:244-246.
24. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999;60:36-40.
25. Ng CH, Chong SA, Lambert T, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 2005;20:163-168.
26. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004;24: 70-78.
27. Schulte P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003;42:607-618.
28. Li Z, Huang M, Ichikawa J, et al. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M(1) muscarinic receptors. Neuropsychopharmacology 2005;30:1986-1995.
29. Sur C, Mallorga PJ, Wittmann M, et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A 2003;100:13674-13679.
30. Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 2005;315: 1278-1287.